Eliquis Proving to Be a Major Growth Driver for Pfizer This Year
Eliquis’s growth trends
Reported as part of Alliance revenues under Pfizer’s (PFE) Innovative Health (or IH) segment, Eliquis’s sales have been witnessing solid growth due to increased penetration of the novel oral anticoagulant (or NOAC) class of drug in multiple markets.
Cardiologists in major markets such as the US and Japan have been consistently prescribing Eliquis, making the drug the top oral anticoagulant in the new-to-brand category.
Interested in PFE? Don't miss the next report.
Receive e-mail alerts for new research on PFE
On April 26, 2007, Pfizer (PFE) and Bristol-Myers Squibb (BMY) announced a collaboration to research, develop, and commercialize its anticoagulant, Eliquis (apixaban). Both companies have been sharing expenses as well as profits and losses on an equal basis.
To learn more about Eliquis, please read Bristol-Myers Capitalizes on Japanese Markets for Its Cardio Drug.
The above chart shows that in 2015, Pfizer’s Alliance revenues increased year-over-year (or YoY) by about 45%, driven mainly by increasing market share of Eliquis. In 2014, Pfizer’s Alliance revenues witnessed a steep decline as the co-promotion agreement with Amgen (AMGN) related to Enbrel in the US and Canada markets expired on October 31, 2013. Additionally, the collaboration agreement for Spiriva with Boehringer Ingelheim also expired in 2014 in multiple key geographies.
Currently, about 3.5 million patients have been prescribed Eliquis. Eliquis is now a tough competition for leading anticoagulant drug, Johnson & Johnson’s (JNJ) Xarelto. As utilization rates continue to rise for Eliquis, the drug is expected to add significantly to Pfizer’s Alliance revenues.
If Eliquis continues with its strong trajectory, it may boost Pfizer’s share price, as well as that of the Vanguard High Dividend Yield ETF (VYM). Pfizer makes up about 2.3% of VYM’s total portfolio holdings.
In the next article, we’ll study the expected growth trends for Pfizer’s Tovias for 2016.